TPG invests $10M in startup Trevi; Arrowhead inks $32M pact with Shire; GSK, Theravance file app on COPD therapy;

Conversations on Twitter :

 @FierceBiotech: Celgene wraps $500M deal to partner with Sutro on next-gen ADCs. Article | Follow @FierceBiotech

@JohnCFierce: Hey, Actelion is (kind of) on a roll, with positive psoriasis data on PhII drug. Handily beats placebo. Article | Follow @JohnCFierce

@RyanMFierce: Interesting how Merck is using GE's experimental imaging agent in Alzheimer's trial for MK-8931. Does this add risk? Report | Follow @RyanMFierce

> New Haven, CT-based Trevi Therapeutics raised $10 million in Series A cash from the venture arm of TPG. The money is being earmarked for research work on T111, an oral extended-release opioid  for the treatment of uremic pruritus. Uremic pruritus is a persistent and debilitating itching in patients on dialysis that has been linked to increased mortality. Release

> Arrowhead Research has inked a deal to collaborate with Shire ($SHPG) on the development of peptide-drug conjugates, with the potential to earn up to $32.8 million in milestones. Shire will also provide research support to Arrowhead. Release

> Lexington, MA-based Avaxia Biologics has raised $6.4 million to fund a first-in-human Phase 1b clinical trial of its oral anti-TNF antibody, AVX-470, for the treatment of ulcerative colitis. Existing investor Cherrystone Angels and new investor Golden Seeds led the round. Also participating in the round were existing investors Beacon Angels, Boston Harbor Angels, Launchpad Venture Group, Mass Medical Angels, and North Country Angels; new investors the Beta Fund, Granite State Angels, the Keiretsu Forum, and Maine Angels; and individual investors. Release

> GlaxoSmithKline ($GSK) and Theravance ($THRX) submitted a regulatory application to the FDA for the once-daily LAMA/LABA combination medicine, UMEC/VI, for patients with COPD. Release

> Oncodesign and the Laboratory for Neurobiology and Gene Therapy at the Department of Neurosciences at the KU Leuven will collaborate with Ipsen on new compounds for Parkinson's disease. Release

Pharma News

@FiercePharma: A blow to Roche's Avastin hopes as NICE rejects it for ovarian cancer. News | Follow @FiercePharma

> NICE slaps down Roche's Avastin for ovarian cancer. Article

> Mylan chief jets to pop singer son's concerts on company aircraft. Story

Medical Device News

 @FierceMedDev: Quidel wins 510(k) for C. difficile molecular Dx. More | Follow @FierceMedDev

@MarkHFierce: More Dx funding--this time for Ortho Kinematics, a spine imaging Dx company--$2M Series B. Item | Follow @MarkHFierce

 @DamianFierce: Medtronic posts more good renal denervation data, but it faces mounting competition from $BSX, $STJ. Story | Follow @DamianFierce

> St. Jude Medical enrolls first patient in cardiac stent imaging guidance trial. Article

> GE licenses Alzheimer's imaging agent to Merck. Report

> Disgraced ex-Home Diagnostics head avoids jail time. News

Pharma Manufacturing News

> Teva puts brakes on $300M Philly warehouse. News

> FDA's counterfeit drug probe sweeps up cancer doc. Article

Biotech Research News

> Acetylon's HDAC drug fights sickle cell disease, beta thalassemia in blood cell studies. Item

> Lifting the mood: Antidepressant could double as diabetes drug. Report

> Engineered viruses rebuild heartbeat. Article

> Rejected diabetes drug wakes up cell memories in Alzheimer's. News

> Gene therapy flips switch in sickle cell disease. Story

And Finally… Scientists at Sweden's Karolinska Institutet have devised plans for a new antibiotic that can fight TB and MRSA. Release

 

Suggested Articles

Astellas will develop Frequency's hearing loss drug outside the U.S. in exchange for $80 million upfront and the promise of $545 million down the line.

Inovio Pharmaceuticals is cutting 28% of its workforce and swinging the ax to a bladder cancer test.

The agency was less likely to go against a recommendation when the panellists were united in their opinion.